IP Library Granted Patent US 8,563,608
Granted Patent B2
US 8,563,608 · App. 13/417,899 · Granted Oct 22, 2013

Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,608
App. No.
13/417,899
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention relates to methods of reducing triglyceride levels in statin-treated subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl.

Claims (9)

1. A method of reducing triglyceride levels in a subject on statin therapy and having a triglyceride level of 500 mg/dl to 1500 mg/dl comprising, administering to the subject 2000 mg to 5000 mg per day of ethyl eicosapentaenoate for 12 weeks to reduce triglycerides in the subject without substantially increasing LDL-C compared to subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl who receive a statin but no ethyl eicosapentaenoate for 12 weeks.

2. The method of claim 1 , wherein the triglycerides in the subject are reduced by at least 30% compared to subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl who receive a statin but no ethyl eicosapentaenoate for 12 weeks.

3. The method of claim 1 , wherein the triglycerides in the subject are reduced by at least 40% compared to subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl who receive a statin but no ethyl eicosapentaenoate for 12 weeks.

4. The method of claim 1 , wherein the triglycerides in the subject are reduced by at least 50% compared to subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl who receive a statin but no ethyl eicosapentaenoate for 12 weeks.

5. The method of claim 1 , wherein the statin is selected from lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin and simvastatin.

6. The method of claim 1 , wherein the 2000 mg to 5000 mg of ethyl eicosapentaenoate is administered to the subject in 4 capsules.

7. The method of claim 6 , wherein the capsules each comprises about 900 mg to about 1 g of ethyl eicosapentaenoate.

8. The method of claim 1 , wherein the 2000 mg to 5000 mg of ethyl eicosapentaenoate is administered in a plurality of capsules providing a daily ethyl eicosapentaenoate dose of 2000 mg to 5000 mg.

9. The method of claim 1 , wherein the 2000 mg to 5000 mg of ethyl eicosapentaenoate is administered to the subject in 4 capsules each comprising about 1 g of ethyl eicosapentaenoate.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: CPPIB CREDIT EUROPE S.À R.L.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 054484/0552 →
SECURITY INTEREST Recorded Dec 21, 2017
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044938/0257 →
PATENT SECURITY ASSIGNMENT AND ASSUMPTION AGREEMENT Recorded Dec 20, 2017
From: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044956/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 029501/0944 →
SECURITY AGREEMENT Recorded Dec 19, 2012
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
Reel/Frame 029499/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2012
From: MANKU, MEHAR; ROWE, JONATHAN
To: AMARIN PHARMA, INC.
Reel/Frame 029220/0725 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2012
From: AMARIN PHARMA INC.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 029220/0789 →